Free Trial
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$1.46
+0.01 (+0.69%)
(As of 11/1/2024 ET)

About Nephros Stock (NASDAQ:NEPH)

Key Stats

Today's Range
$1.46
$1.48
50-Day Range
$1.36
$1.89
52-Week Range
$1.36
$4.04
Volume
893 shs
Average Volume
15,190 shs
Market Capitalization
$15.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Nephros Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 53% of companies evaluated by MarketBeat, and ranked 568th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nephros has received no research coverage in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nephros' valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently decreased by 76.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nephros has recently decreased by 76.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nephros has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

NEPH Stock News Headlines

Nephros launches HydraGuard 20″ UltraFilter
Why Buffett, Bezos, & Congress Are Piling Into This One Sector
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…
MMTC Micro Imaging Technology, Inc.
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $3.46 at the beginning of the year. Since then, NEPH stock has decreased by 57.8% and is now trading at $1.4589.
View the best growth stocks for 2024 here
.

Nephros, Inc. (NASDAQ:NEPH) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.02. The firm earned $3.25 million during the quarter. Nephros had a negative trailing twelve-month return on equity of 15.64% and a negative net margin of 9.40%.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NEPH
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+242.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-1,580,000.00
Pretax Margin
-9.40%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$0.80 per share

Miscellaneous

Free Float
10,112,000
Market Cap
$15.38 million
Optionable
Not Optionable
Beta
1.18
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners